

Index

- A–B–C charts, 172
 A–B–C model of behavior, 171
 Aberrant Behavior Checklist (ABC), 49
 acetylcholinesterase inhibitors, 59, 142
 acute stress disorder, 100–1
 adaptive functioning deficits, 22, 24–6
 ADHD. *See* attention-deficit/hyperactivity disorder
 adjustment disorders, 101–2
 Adult Behavior Checklist (ABCL), 50
 affective disorders. *See* mood disorders
 age of onset, as diagnostic criterion, 26
 aging-related health problems, 233
 aggressive behavior, 209
 assessment in children, 185
 behavioral interventions, 175
 carers' perceptions of causes, 271–3
 cognitive-behavioral interventions, 211–12
 course over time, 226
 inpatient admission, 253
 pharmacotherapy, 142, 187, 285
 prevalence, 224
 agoraphobia, 91
 agreeableness (A), 112
 alcohol misuse, 216
 Alzheimer's disease, 57
 Down syndrome and, 57–60
 pharmacotherapy, 59, 142
 American Association for Intellectual and Developmental Disorders (AAIDD), 16, 24, 27
 American Psychiatric Association (APA), 5, 16, 18
 amphetamines, 134, 187
 amyloid deposition, Down syndrome, 58
 anger, interventions, 157, 211–12
 animal models, 202
 anticonvulsants. *See* antiepileptic drugs
 antidepressants, 141
 anxiety disorders, 93
 autism spectrum disorders, 143
 children, 187
 depression, 83, 142
 antiepileptic drugs
 behavioral problems, 140
 epilepsy, 249
 refractory epilepsy, 246
 side effects, 144, 234–5, 249
 West syndrome, 247
 antipsychotic agents
 anxiety disorders, 93
 children, 187
 extra-pyramidal side effects, 70, 144
 first-generation (FGA), 140
 problem behaviors, 142, 228, 285
 schizophrenia spectrum disorders, 70–1, 141
 second-generation. *See* atypical antipsychotics
 atypical antipsychotics
 antisocial behavior, 209. *See also* offending behavior
 assessment in children, 185
 antisocial personality disorder, 110–11
 anxiety, 89, 99
 in autism spectrum disorders, 120–2
 Anxiety, Depression and Mood Scale (ADAMS), 47, 83
 anxiety disorders, 89–96
 clinical presentation, 90–1
 diagnostic tools, 48, 91–7
 in autism spectrum disorders, 93, 121–5
 in children, 183
 in Williams syndrome, 198–9
 management and treatment, 92–5
 prevalence, 90
 risk factors, 91
 stepped-care model, 93
 Anxiety Disorders Interview Schedule, 184
 apolipoprotein E4 (Apo E4) allele, 59
 APP gene, increased expression, 58
 Arc (National Association of Parents and Friends of Mentally Retarded Children), 2
 aripiprazole, 140, 143
 arson. *See* firesetting
 Asian countries, service provision, 9
 assertive community treatment (ACT), 71, 255
 assessment
 behavioral, 171–9
 children with ID, 183–4
 epidemiological studies, 37–9
 assessment instruments and rating scales, 45–51
 choosing, 50
 new developments, 51
 screening, 46
 screening vs. diagnostic, 46
 self-report vs. informant-report, 45
 standardized diagnostic interviews, 50
 Assessment of Dual Diagnosis (ADD), 47, 82–3
 Assimilation of Problematic Experiences model, 153
 asylums, 2
 atomoxetine, 141
 attention-deficit/hyperactivity disorder (ADHD), 129–35
 areas for future research, 134
 assessment, 131–2

- attention-deficit/
hyperactivity disorder (ADHD)
(cont.)
 diagnostic criteria, 129–30,
 185
 diagnostic validity in ID, 131
 epidemiology, 130
 impact, 131
 longitudinal course, 182
 management, 132–4
 pharmacotherapy, 133–4,
 141, 238
attention function, aggressive
 behavior, 272
attribution model, carer stress
 and, 269
atypical antipsychotics. *See*
 also risperidone
 bipolar disorder, 84
 problem behaviors, 140
 schizophrenia spectrum
 disorders, 70–1
 side effects, 70, 144
auditory hallucinations, 69
Australia, service provision, 9
Autism Diagnostic Instrument
 (ADI)/Autism Diagnostic
 Observation Schedule
 (ADOS), 184
autism spectrum disorders
 (ASD), 28–9, 119–26
 anxiety symptoms and
 disorders, 93, 120–5
 assessment tools, 29, 184
 clinical implications of
 mental illness, 123
 diagnosis of mental illness,
 121, 124
 differential diagnosis,
 28–9, 68, 120–1
 management and treatment,
 124–5
 pharmacotherapy, 125, 140–
 1, 144
 Prader–Willi syndrome, 201
 prevalence of mental illness,
 122–3
 risk of mental illness, 119–20
 service provision, 8, 253
aversive interventions,
 problem behaviors, 174
avoidant behavior, 102, 176

barbiturates, 140, 249
Beck Depression Inventory
 (BDI), 48, 92

Behavior Problems Inventory
 (BPI), 50
behavioral and psychological
 symptoms of dementia
 (BPSD), Down
 syndrome, 59
behavioral approach, 171–8
behavioral assessment, 171–2,
 177
behavioral equivalents, 79, 280
behavioral interventions,
 171, 172–8
 challenging behavior,
 174–6
 focusing on consequences,
 173–4
 for children, 187
 implementation in practice,
 176–7
 modifying antecedent
 stimuli, 173
 symptoms of psychiatric
 disorders, 176
behavioral phenotypes,
 196–202
 age-related changes, 198
 complex interactions,
 198
 examples, 198–201
 future areas for research,
 201–2
 multiple domains, 197
 social and family context,
 198
 total vs. partial specificity,
 197
 within-syndrome variability,
 197
behavioral problems. *See*
 problem behaviors
benzodiazepines, 93, 140, 249
bereavement, 103–5
beta-adrenergic blockers, 141,
 187
bipolar disorder
 assessment instruments, 83
 diagnostic features, 79–80
 epidemiology, 81
 etiology, 81
 pharmacotherapy, 84, 142,
 237–8
 psychosocial interventions,
 84
Bipolar Mood Chart, 83
birth complications,
 schizophrenia risk, 66

BOLD (Becoming Older with
 Learning Disability)
 study, 56–7
borderline intellectual
 functioning (BIF), 27
brain damage
 causing ID, 29
 prolonged seizures causing,
 243
 traumatic, epilepsy and ID,
 244
Brief Symptom Inventory
 (BSI), 46
burnout, carer, 270

CAMDEX-DS, 49
cancer
 risks, 233
 screening, 232
cannabis use, 66
carbamazepine, 140, 187
carers. *See also* family(ies);
 parents
 burden of psychosis and ID,
 71
 employed. *See* staff
 experiences of services,
 262–7
 impact of problem
 behaviors, 269–74
 perceptions of causes of
 aggression, 271–3
 positive aspects of caring,
 270–1
 stress, and cognitive
 variables, 269–70
 training and support, 133,
 186, 273–4
Cattell–Horn–Carroll model
 of intelligence, 23
celiac disease, 234
cerebral palsy, 29
challenging behavior. *See*
 problem behaviors
Challenging Behaviour
 Perception
 Questionnaire, 270
children, psychopathology of,
 181–92
 ADHD, 131, 133–4, 182
 case examples, 187–92
 clinical assessment, 183–4
 depression, 81, 183
 developmental level and
 cognitive ability, 184–5
 epilepsy, 242–3

- management principles, 186–7
- multiple disabilities and medical illness, 185
- pharmacotherapy, 141, 143, 187
- phenomenology, 182–3
- prevalence, 181
- psychosocial and family factors, 185–6
- transitional services, 124, 265
- cholinesterase inhibitors, 59, 142
- citalopram, 83, 141
- classification of ID, 15–21, 30
- future perspectives, 17–19
- neurodevelopmental perspective, 21
- terminology, 19–21
- classification of problem behaviors, 226–7
- classification systems. *See* DSM-5; ICD-10; ICD-11
- clomipramine, 142
- clonidine, 141, 187
- clozapine, 71, 83
- cognitive assessment
- children with ID, 184
- diagnosis of ID, 24
- longitudinal, in dementia, 56
- cognitive-behavioral therapy (CBT), 161–7
- adaptations for ID, 165
- anger and aggression, 211–12
- anxiety disorders, 94–5
- autism spectrum disorders, 125
- challenges of using, 162–5
- depression, 84
- development of trials, 165
- firesetting behavior, 215
- for children, 186
- future directions, 166
- impact of ID, 164–5
- sexually aggressive behavior, 212–13
- theoretical basis, 161–2
- cognitive deficit models, 162
- cognitive distortion models, 162
- cognitive skills training, offenders, 216–17
- communication impairments, autism, 119
- community-based services. *See also* outpatient services
- historical context, 2–4
- implementing behavioral interventions, 176–7
- normalization concept, 3–4
- offender populations, 209
- psychosis and ID, 71
- service users' experiences, 265
- community intellectual disability teams, 7
- conduct disorder
- assessment, 185
- classification, 226
- conscientiousness (C), 112
- constipation, 234
- Core and Cluster program, 4
- cortical development, malformations of, 245
- countertransference, 155–6
- course of IDD, 27–8
- criminal offending. *See* offending behavior
- crisis services, 282
- DASH-II, 47
- anxiety disorders, 92
- mood disorders, 83
- schizophrenia spectrum disorders, 69
- DBC. *See* Developmental Behavior Checklist
- DC-LD (*Diagnostic Criteria - Learning Disability*)
- ADHD, 130
- anxiety disorders, 89
- epidemiological studies, 36, 39–40
- mood disorders, 78
- schizophrenia spectrum disorders, 65, 69
- deafness, 185
- death, understanding of concept, 103
- defense mechanisms, 154–6
- defiant behavior, assessment, 185
- deinstitutionalization, 3–13, 252, 280
- impact on mental health problems, 4
- normalization concept and, 4–13
- offending behavior and, 209
- delirium, 56
- delusions, 69, 176
- dementia, 55–60
- diagnosis, 55–6
- Down syndrome and, 57–60
- epidemiological studies, 56–7
- pharmacotherapy, 59, 142
- prevalence and incidence, 56–7
- risk factors, 57
- screening instruments, 48–9
- subtypes, 57
- Dementia Questionnaire for Learning Disabilities (DMR), 48–9
- Dementia Scale for Down Syndrome (DSDS), 48–9
- dental care needs, 232
- dependent personality disorder, 110
- depression
- assessment instruments, 47–8, 82–3
- behavioral interventions, 176
- diagnostic features, 78–9
- etiology, 81–2
- in autism spectrum disorders, 121–2, 124
- in childhood, 81, 183
- pharmacotherapy, 83, 142
- prevalence, 80–1
- psychosocial interventions, 84
- risk factors, 163
- depressive factor/dimension, 227–8
- development of IDD, 27–8
- Developmental Behavior Checklist (DBC), 50
- adult version (DBC-A), 92
- children, 182–3
- Hyperactivity Index, 132–6
- diagnosis, psychiatric assessment instruments and rating scales, 45–51
- autism spectrum disorders, 121, 124
- children with ID, 182
- epidemiological studies, 37–8

- diagnosis, psychiatric (cont.)
 ID/IDD, 21–9
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.*
 See DSM-5
- Diagnostic Assessment for the Severely Handicapped–II.
 See DASH-II
- diagnostic criteria for ID/IDD, 21–6
 adaptive functioning, 24–6
 age of onset, 26
 intelligence, 22–4
- Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities/Mental Retardation.* See DC-LD
- Diagnostic Interview for Social and Communication Disorders (DISCO), 29
- diagnostic interviews, structured, 46, 50
- Diagnostic Manual – Intellectual Disability.* See DM-ID
- diagnostic overshadowing, 99, 124, 231
- dialectical behavior therapy (DBT), personality disorders, 111
- differential diagnosis of IDD, 28–9
- differential reinforcement (DR), 173
- difficulties, 20
- DiGeorge syndrome (velocardiofacial syndrome), 67, 143
- disability
 concept of ID as a, 16–17
 defined, 25
- Disorders of Intellectual Development, 19, 30
- divalproex, 84, 238
- DM-ID (*Diagnostic Manual – Intellectual Disability*)
 ADHD, 130
 anxiety disorders, 89
 epidemiological studies, 39
 mood disorders, 78–9
 PTSD, 102
 schizophrenia spectrum disorders, 65
- donepezil, 59, 142
- Down syndrome, 236
 age-related changes, 198
 Alzheimer's disease, 57–60
 animal model, 202
 family and social context, 198
 medical illness, 233
 pharmacotherapy of dementia, 59, 142
 schizophrenia spectrum disorders, 68
 severe, adverse behavioral changes, 199–200
- Dravet syndrome, 245, 247
- drug therapy. See psychopharmacology
- DSM-5
 anxiety disorders, 89
 applicability to children with ID, 182
 classification of ID, 16, 30
 diagnostic criteria for ID, 21–6
 neurocognitive disorder, 55
 neurodevelopmental disorders, 21
 personality disorders, 111, 114
 problem behaviors, 226
 terminology for ID, 15, 18–20, 30
- dual diagnosis, 5
- Dual Disability Services, Australia, 9
- DYRK1A* gene, 58
- Eastern Nebraska Community Office of Retardation (ENCOR), 4
- eating disorders, 235
- ego, 151–2
- emotion dysregulation, 119, 228
- emotion dysregulation-problem behavior, 227–8
- emotional intelligence, Goleman's, 23
- Emotional Problems Scale, 210
- emotional states, triggering aggression, 273
- epidemiology of psychiatric comorbidity in adults, 34–40
- changes in diagnostic manuals and, 39
- definition, measurement, and assessment methods, 37–8
- geographical, cultural and linguistic spread, 39–40
- inclusion of physiological assessment, 38–9
- prevalence data, 35–6
- sampling methodology, 37
- studies reviewed, 34–5
- epilepsy, 185, 242–9
 as cause of ID, 243–4
 disorders causing ID plus epilepsy, 244–6
 epidemiology, 242–3
 genetics, 245
 ID as cause of, 244
 psychiatric comorbidity, 225, 248
 refractory, 246
 syndromes, associated with ID, 246–8
 treatment, 248–9
- epileptic encephalopathy, 244
- escape function, aggressive behavior, 272
- ethnic minority status
 schizophrenia risk, 66
 service users' experiences, 266
- eugenics, 2, 4
- Europe, service provision, 7–8
- everolimus, 245
- extra-pyramidal side effects (EPSEs), 70, 144
- extraversion/introversion (E), 112, 114
- family therapy, 71, 186
- family(ies). See also parents
 behavioral phenotypes and, 198
 childhood psychopathology and, 185–6
 cognitive variables and stress, 269–70
 experiences of services, 262–7
 impact of problem behaviors, 269–74
 perceptions of causes of aggression, 271–3
 positive aspects of caring, 270–1

- training and support, 133, 186, 274
- fear, 89
- Fear Survey for Adults with Mental Retardation (FSAMR), 48, 92
- fetal alcohol spectrum disorder, 143
- firesetting, 209
therapeutic interventions, 214–15
- Five Factor Model (FFM) of personality, 111–12, 114
- 5p-syndrome, 197
- fluoxetine, 83
- Flynn effect, 22–4
- forensic populations, 207–18,
See also offending behavior
personality disorders, 110–11
prevalence of ID, 207
psychotic illness and ID, 66
recidivism rates, 207–8
- forensic risk assessment, 209–11
- foster care, 185
- fragile X syndrome (FXS), 236
behavioral phenotype, 197, 198
pharmacotherapy, 142–3
- free-association, 154
- Freud, Sigmund, 151–2, 156
- frontal type dementia, 57
- functional analysis (FA) of behavior, 172
- functional assessment questionnaires, 172
- functional communication training (FCT), 173
- Gardner model of intelligence, 23
- gastroesophageal reflux disease (GERD), 234
- gastrointestinal (GI) cancer, 233
- gastrointestinal problems, 234
- generalized anxiety disorder presentation, 90
prevalence, 90
Williams syndrome, 199
- generic mental health services.
See mainstream mental health services
- genetic syndromes, 203–4
- ADHD, 130
- anxiety disorders, 91
- as models for psychiatric disorders, 201–2
- behavioral phenotypes, 196–201
- development and course, 28
- epilepsy and ID, 245
- evaluation and diagnosis, 236–7
- mood disorders, 82
- schizophrenia spectrum disorders, 67–8
- Glasgow Anxiety Scale for people with an Intellectual Disability (GAS-ID), 48, 92
- Glasgow Depression Scale for people with a Learning Disability (GDS-LD), 48, 82
- global developmental delay (GDD), 29
- goal-directed behavior, 273
- Goleman's emotional intelligence, 23
- grief
complicated (pathological), 103–5
normal reactions to, 103
- group-based interventions
anger and aggression, 212
- firesetting behavior, 215
- sexually aggressive behavior, 212–13
- guanfacine, 141
- guided self-help (GSH),
anxiety disorders, 94–5
- hallucinations, 69
- haloperidol, 187, 285
- Hamilton Depression Rating Scale, 48
- HCR-20, 210
- head trauma/head banging,
repeated, 57
- headache, 233
- health condition, 16
categorization of ID as, 17–28
- hearing impairment, 185
- Helicobacter pylori* infections, 232
- hemi-megalencephaly, 245
- hemispherectomy, cranial, 29, 245
- historical perspective of services, 1–7
- holistic approach, need for, 281
- Hospital Anxiety and Depression Scale (HADS), 92
- hospital services. *See* inpatient services
- human rights, 2
- hybrid service models of care, 256–7, 283
- hyperkinetic disorder, 129
- hyperphagia, 197, 200–1
- ICD-10
anxiety disorders, 89
applicability to children with ID, 182
classification of ID, 16, 18–19
diagnostic criteria for ID, 21
disability concept of ID and, 17
hyperkinetic disorder, 129
problem behaviors, 226–7
revision working group.
See under World Health Organization
- ICD-11
classification of ID, 17–19, 30
neurodevelopmental approach to ID, 21
problem behaviors, 226
proposed terminology for ID, 19–21, 30
subtyping of IDD, 27
- ID. *See* intellectual disabilities
- IDD. *See* Intellectual Developmental Disorder
- impairment, 20
- Improving Access to Psychological Therapies (IAPT's) teams, 94
- informant-report assessment instruments, 45
- inpatient services
clinical outcomes, 254
patient profiles, 253
schizophrenia spectrum disorders, 72
service users' experiences, 264–5

- inpatient services (cont.)
strengths and limitations, 255–6
- institutional care, 1–2, 252
children living in, 186
shift away from. *See* deinstitutionalization
- integrated service models of care, 256–7, 283
- Intellectual Developmental Disorder (IDD)
as neurodevelopmental disorder, 21
development and course, 27–8
diagnostic criteria, 21–6
differential diagnosis, 28–9
introduction by DSM-5, 15, 18–20
proposed use in ICD-11, 20–1, 30
subtyping, 26–7
- intellectual disabilities (ID)
as a health condition, 17–28
classification, 15–21, 30
diagnosis, 21–9
differential diagnosis, 28–9
disability concept, 16–17
meta-syndrome concept, 18
subtyping, 26–7
terminology. *See* terminology for ID
- Intellectual Disability (Intellectual Developmental Disorder) (ID (IDD))
adoption by DSM-5, 16, 19–20, 30
diagnostic criteria, 21–6
intelligence, 22–4
intensive case management, 255
internal objects, 156
International Classification of Diseases. *See* ICD
- International Classification of Functioning, Disability and Health (ICF), 16, 20, 24
- international trends, service provision, 7–10
- introversion. *See* extraversion/introversion
- IQ score
as diagnostic criterion for ID, 21–3
- borderline intellectual functioning, 27
limitations, 23–4
offending behavior and, 208
subtyping based on, 27
- Ireland, service provision, 10
- Itard, Jean, 2
- Lancaster and Northgate Trauma Scales (LANTS), 102–8
- Landau–Kleffner syndrome, 244, 248
- Lennox–Gastaut syndrome, 246, 248
- Lesch–Nyhan syndrome, 197
- Lewy body dementia, 57
- life events, adverse, 99–100
acute stress reaction, 100–1
adjustment disorders, 101–2
increased frequency, 100
mood disorders, 82
problem behaviors and, 226
schizophrenia risk, 66
- life experiences, psychological impact, 163–4
- lithium, 140, 187, 235
- loxapine, 237
- mainstream mental health services, 252
attitudes of ID staff to, 282
client groups suited to, 256
clinical outcomes, 254–5
historical context, 4–6
patient profiles, 253–4
service users' experiences, 264–5
strengths and limitations, 256
- Malan's triangles, 156–7
- malformations of cortical development, 245
- mania. *See also* bipolar disorder
assessment instruments, 83
symptoms, 80
- matrix model, for services, 6
- Matson Evaluation of Drug Side Effects (MEDS), 70
- MECP2 gene deletion, 236, 237
- medical conditions, comorbid, 231–8
- aging-related, 233
children, 185
clinical approach, 235–6
screening for, 232
- medication. *See* psychopharmacology
- memantine, 59, 142
- menstrual cramps/discomfort, 233
- mental health of ID (MHID) field, 279–86
basic tenets, 279–80
definitions and terminology, 279
mental health vs. challenging behaviors, 280–1
research, 283–6
service provision, 281–3
- mental health of ID services. *See* services
- mental health problems, comorbid. *See* psychiatric disorders, comorbid
- mental retardation
terminology, 15
use in ICD-10, 16
- metabolic syndrome, 70
- meta-syndrome concept of ID, 18
- methylphenidate
ADHD, 134, 141, 187
velocardiofacial syndrome, 143
- migraine, 233
- mild cognitive impairment, 18
- Mini Psychiatric Assessment Schedule for Adults with Developmental Disabilities (Mini PAS-ADD), 46
- minocycline, 143
- Monthly Sleep Chart, 83
- Mood and Anxiety Semi-Structured (MASS) interview, 50, 83
- mood disorders, 78–85
assessment instruments, 47–8, 82–3
diagnostic features, 78–80
epidemiology, 80–1
etiology, 81–2
in autism spectrum disorders, 124

- intervention and treatment, 83–4
 pharmacotherapy, 83–4, 142
 service provision, 254
 Mood, Interest, and Pleasure Questionnaire (MIPQ), 48
 mood stabilizers
 behavioral problems, 140
 bipolar disorder, 84, 142
 side effects, 144
 motivation
 intrinsic vs. extrinsic, 113
 values providing, 113
 Motivation Assessment Scale (MAS), 172
 naltrexone, 141–2
 National Association for the Dually Diagnosed (NADD), 8
 National Association of Parents and Friends of Mentally Retarded Children (Arc), 2
 National Institute for Health and Care Excellence (NICE)
 anxiety disorders, 93–4
 depression, 83
 quality of services, 263
 negative symptoms, 69
 NEO Personality Inventory (NEO-PI; NEO-PI-R), 110, 112
 neurocognitive disorder, 55
 neurodegenerative disorders, 29
 neurodevelopmental disorders (NDD), 21
 neurofibrillary tangles, 58
 neurological problems, 234
 neuronal antibodies, 246
 neurosurgery, for epilepsy, 29, 245, 249
 neuroticism (N), 112, 114
 NICE. *See* National Institute for Health and Care Excellence
 NMDA-receptor antibodies, 246
 non-contingent reinforcement (NCR), 173–4
 normalization, 3–4
 Northgate, Cambridge, and Abertay Pathways (NCAP) project, 209
 obesity, 237
 object relations theory, 156
 obsessive-compulsive disorder (OCD), 120, 122
 offending behavior, 207–18,
See also forensic populations
 alcohol misuse, 216
 cognitive skills training, 216–17
 intellectual functioning and, 208
 interventions, 209–17
 nature, 209
 psychodynamic psychotherapy, 153
 recidivism rates, 207–8
 risk assessment, 209–11
 openness (O), 112
 operant conditioning, 187
 opiate antagonists, 141, 187
 oppositional defiant disorder (ODD), 131, 226
 oral health needs, 232
 osteoporosis/osteopenia, 233
 outpatient services. *See also* community-based services
 clinical outcomes, 254–5
 patient profiles, 253–4
 strengths and limitations, 255–6
 oxcarbazepine, 140
 PAC (Psychopathology in Autism Checklist), 47–52, 121, 122–3
 pain syndromes, 233
 panic disorder, 90
 parents. *See also* carers; family(ies)
 experiences of services, 264
 grief responses to death of, 104–5
 mental health problems in, 186
 positive aspects of caring, 270–1
 stress and burnout, 270
 training and support, 133, 186
 paroxetine, 83
 PAS-ADD, 38, 40, 50
 anxiety disorders, 92
 Checklist, 46
 Clinical Interview, 50
 Mini, 46
 mood disorders, 83
 schizophrenia spectrum disorders, 69
 PCL-R, 111
 periodontal disease, 232
 personality
 assessment, 111–14
 Five Factor Model (FFM), 111–12, 114
 psychiatric disorders and, 114
 personality disorders, 109–11
 difficulties in diagnosing, 109–10
 factor analysis, 110
 prevalence, 109–10
 psychiatric disorders and, 114
 treatment studies, 111
 pharmacotherapy. *See* psychopharmacology
 phobic anxiety disorders, 91
 behavioral interventions, 176
 Williams syndrome, 199
 physical discomfort, triggering aggression, 273
 pica, 226, 234
 behavioral interventions, 175
 PIMRA (Psychopathology Inventory for Mentally Retarded Adults), 47–52, 92
 Pinel, Phillipe, 1
 Planning, Attention, Simultaneous and Successive (PASS) model of intelligence, 23
 Positive Contributions Scale (PCS), 271
 post-traumatic stress disorder (PTSD), 102–3
 acute stress disorder and, 101
 autism spectrum disorders, 125
 presentation and diagnosis, 102–3

- Prader–Willi syndrome (PWS), 200–1, 236
 age-related changes, 198
 autism spectrum disorders, 201
 cognitive processing style, 197
 hyperphagia, 197, 200–1
 pharmacotherapy, 143
 psychotic illness, 68, 201
 severe psychiatric illness, 200–1
 preference assessment, 172
 pregabalin, 93
 pregnancy complications, schizophrenia risk, 66
 prisoners. *See* forensic populations
 problem (challenging)
 behaviors, 224–8
 assessment tools, 49
 behavioral interventions, 174–6
 carer and family perspectives, 269–74
 carers' perceptions of causes, 271–3
 classification, 226–7
 course over time, 226
 Down syndrome, 199–200
 interdisciplinary research, 286
 management issues, 228
 mental illness and, 224–8, 280–1
 pharmacotherapy, 140–2, 228
 prevalence in ID, 224
 psychodynamic psychotherapy, 153
 services, 253, 255, 283
 prolonged grief disorder, 103, 104
 Psychiatric Assessment Schedule for Adults with Developmental Disabilities. *See* PAS-ADD
 psychiatric disorders, comorbid
 ADHD, 131
 autism spectrum disorders, 119–26
 behavioral interventions, 176
 carer and family perspectives, 269–74
 clinical approach, 237–40
 diagnosis. *See* diagnosis, psychiatric
 epidemiology in adults, 34–40
 epilepsy, 225, 248
 historical perspective, 7–11
 impact of
 deinstitutionalization, 4
 in children, 181–92
 international trends in services, 7–10
 medical illness and, 231–8
 personality, personality disorders and, 114
 pharmacotherapy, 141–2
 prevalence, 35–6, 181, 280
 problem behaviors and, 224–8, 280–1
 psychoanalysis, 151
 psychodynamic psychotherapy, 151–8
 evidence base, 152–4
 information gathering, 154–5
 recontextualization, 155–6
 suitability criteria, 152
 therapeutic frame, 154
 therapists' activities, 154–7
 Psychopathology checklists for Adults with Intellectual Disability (P-AID), 50
 Psychopathology in Autism Checklist (PAC), 47–52, 121–3
 Psychopathology Inventory for Mentally Retarded Adults (PIMRA), 47, 92
 psychopharmacology, 139–45
 children with ID, 141, 143, 187
 guidelines, 144–5
 past, 140–1
 side effects, 144, 235
 specific ID-related disorders, 142–4
 specific psychiatric disorders, 141–2
 psychosocial factors, psychopathology of children, 185–6
 psychosocial interventions
 alcohol misuse, 216
 anxiety disorders, 93–5
 mood disorders, 84
 schizophrenia spectrum disorders, 71
 psychotic illness. *See* schizophrenia spectrum disorders
 psychotropic medication. *See* psychopharmacology
 PTSD. *See* post-traumatic stress disorder
 Questions About Behavioural Function (QABF) scale, 172
 rapamycin (sirolimus), 245
 rating scales. *See* assessment instruments and
 recidivism rates, 207–8
 recontextualization, 155–6
 Reiss Screen for Maladaptive Behaviour (RSMB), 47, 82
 research, mental health of ID field, 283–6
 residential care. *See* institutional care
 response cost, 174
 restraint, physical and mechanical, 174
 Rett syndrome, 197, 236–7
 risk assessment, forensic, 209–11
 risperidone
 ADHD, 134
 aggressive behavior, 142, 285
 autism spectrum disorders, 140, 143
 problem behaviors, 140, 142, 187
 rivastigmine, 59
 Royal College of Psychiatrists, 5, 10
 Diagnostic Criteria – Learning Disability.
 See DC-LD
 Rubinstein–Taybi syndrome, 237
 SAINT self-help tool, 51, 95
 scatterplots, behavioral, 171
 schizophrenia spectrum disorders (SSDs), 65–73

- associated genetic conditions, 67–8
- autism spectrum disorders and, 123–4
- differential diagnosis, 68, 120
- management, 70–1
- neurodevelopmental model, 66–7
- outcome/prognosis, 72
- pharmacotherapy, 70–1, 141
- Prader–Willi syndrome, 68, 201
- prevalence, 65–6
- recognition and diagnosis, 68–9
- risk factors, 66
- service provision, 71–2, 254
- screening instruments, 45–9
- anxiety disorders, 48
- behavioral problems, 49
- dementia, 48–9
- mood disorders, 47–8
- psychopathology, 46–7
- vs. diagnostic instruments, 46
- screenings, basic healthcare, 232
- second-generation antipsychotics. *See* atypical antipsychotics
- seizures. *See also* epilepsy as cause of ID, 243–4
- in Down syndrome dementia, 60
- intellectual function and, 243
- selective serotonin reuptake inhibitors (SSRIs), 141, 187
- anxiety disorders, 93, 141
- autism spectrum disorders, 143
- depression, 83
- side effects, 235
- self-injurious behavior (SIB) behavioral interventions, 175
- course over time, 226
- pharmacotherapy, 142, 187
- prevalence in ID, 224
- PTSD, 103
- self-regulation theory of illness behavior, 270
- self-report assessment instruments, 45
- Self-Report Depression Questionnaire (SRDQ), 48, 82
- sensory stimulation, hypersensitivity to, 120
- separation distress, bereavement-related, 103, 105
- service users, experiences of services, 262–7
- services, 252–8, 281–3
- barriers to access, 231
- clinical outcomes, 254–5
- community-based. *See* community-based services
- deinstitutionalization. *See* deinstitutionalization
- historical context, 1–7
- integrated/hybrid models, 256–7, 283
- international trends, 7–10
- mainstream. *See* mainstream mental health services
- normalization concept, 4–13
- offenders with ID, 209
- patient profiles, 253–4
- pros and cons of different models, 255–7
- service users' and carers' experiences, 262–7
- specialized. *See* specialized mental health services
- transition from childhood to adulthood, 124, 265
- Severe Impairment Battery, 56
- severe myoclonic epilepsy of infancy. *See* Dravet syndrome
- sex offenders, 209
- therapeutic interventions, 212–14
- sexual abuse, 100
- sexuality, 235
- sexually transmitted diseases, 235
- Short Dynamic Risk Scale (SDRS), 210
- Shultz Mini-Mental State Exam, 49
- side effects, medication, 144, 235
- sirolimus (rapamycin), 245
- skills training alcohol misuse, 216
- offending behavior, 215, 216–17
- Smith–Magenis syndrome, 197
- social context behavioral phenotypes, 198
- mental ill-health, 163
- social phobia, 91
- social skills training, firesetting behavior, 214
- specialized mental health services, 252, 283
- client groups suited to, 256
- clinical outcomes, 254–5
- historical context, 5
- international trends, 7, 9
- patient profiles, 253–4
- service users' experiences, 264–5
- staff attitudes to mainstream services, 282
- strengths and limitations, 256
- specific learning disorders (SLD), 29
- spiritual beliefs, 236
- staff (paid carers) impact of problem behaviors, 269–74
- perceptions of causes of aggression, 271–3
- positive aspects of caring, 271
- qualities of good, 266
- service users' experiences, 264–5
- training, 273
- Staff Positive Contributions Questionnaire (SPCQ), 271
- Standardized Assessment of Personality (SAP), 109–15
- START model, 8
- state-dependent intellectual impairment, 244
- Static-99, 210
- stereotypy, behavioral interventions, 175–6
- stigmatization psychological impact, 163, 163–4
- service provision and, 282
- stimulant medications, 134, 141, 187

- stress, 99
 acute reactions, 100–1
 adjustment disorders,
 101–2
 in carers and families,
 270
 problems in autism, 120
 reactions in ID, 99–102
 substance abuse, 235
 subtyping of IDD, 26–7
 suicide, 81
 Suitability for Psychotherapy
 Scale, 152
 swallowing difficulties,
 234
- terminology for ID, 15,
 19–21
 DSM-5, 15, 18–20, 30
 ICD-10, 16
 proposed for ICD-11,
 19, 20–1, 30
 Therapy Expectation Measure,
 165
 timeout, 174
 transference, 156
 transition from childhood to
 adulthood, service
 provision, 124, 265
- trauma, psychological, 100,
 102, *See also* post-
 traumatic stress disorder
 traumatic brain injury,
 epilepsy and ID, 244
 traumatic distress,
 bereavement-related, 103
 tricyclic antidepressants, 141,
 143, 187
 tuberous sclerosis complex,
 245, 247
 22q11.2 deletion syndrome
 (velocardiofacial
 syndrome), 68, 143
 212 Multi-Centre Risk Study,
 210
- United States (US), service
 provision, 4–5, 8
 Usher syndrome, 68
- valproic acid/divalproex, 84, 238
 vascular dementia, 57
 velocardiofacial syndrome
 (VCFS), 68, 143
 vigabatrin, 247, 249
 Violence Risk Appraisal Guide
 (VRAG), 210
 vision problems, 232
- vitamin-D deficiency, 57
 volition, expression of, 273
 voltage-gated potassium-
 channel complex
 antibodies, 246
- West syndrome, 247
 Williams syndrome
 behavioral phenotype,
 198, 198–9
 pharmacotherapy, 143
 Wolfensburger, W., 3
 World Health Organization
 (WHO)
 Atlas on ID (2007), 2
 classification of ID, 16
 ICD-10 revision working
 group (IAGRMR), 15, 18,
 20–1, 27
 World Psychiatric Association
 (WPA)
 Intellectual Disability
 section (WPA-SPID),
 17–28
 medication guidelines,
 145
- Zung Self-Rating Depression
 Scale, 48